<H1>Chapter DOI: 10.1007/978-1-60327-829-4_25<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>51</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>51</td></tr><tr><td>BibStructured Count</td><td width="10%">51</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>39</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>2</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_25</td><td>BibArticle</td><td>Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411&#8211;5.</td><td><a href=http://dx.doi.org/10.1038/332411a0>10.1038/332411a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_25</td><td>BibArticle</td><td>Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989;86:2863&#8211;7.</td><td><a href=http://dx.doi.org/10.1073/pnas.86.8.2863>10.1073/pnas.86.8.2863</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_25</td><td>BibArticle</td><td>Kimura S, Kasuya Y, Sawamura T, et al. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: structure&#8211;activity relationships of big endothelin-1. J Cardiovasc Pharmacol 1989;13 Suppl 5:S5&#8211;7.</td><td><a href=http://dx.doi.org/10.1097/00005344-198900135-00003>10.1097/00005344-198900135-00003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_25</td><td>BibArticle</td><td>Battistini B, D&#8217;Orleans-Juste P, Sirois P. Biology of disease. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600&#8211;28.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_25</td><td>BibArticle</td><td>Casey ML, Byrd W, MacDonald PC. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 1992;74:223&#8211;5.</td><td><a href=http://dx.doi.org/10.1210/jc.74.1.223>10.1210/jc.74.1.223</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_25</td><td>BibArticle</td><td>Prayer-Galetti T, Rossi GP, Belloni AS, et al. Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J Urol 1997;157:2334&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(01)64776-1>10.1016/S0022-5347(01)64776-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_25</td><td>BibArticle</td><td>Lagenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol 1993;150(2 Pt 1):495&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_25</td><td>BibArticle</td><td>Saita Y, Yazawa H, Koizumi T, et al. Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells. Eur J Pharmacol 1998;349:123&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/S0014-2999(98)00183-6>10.1016/S0014-2999(98)00183-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_25</td><td>BibArticle</td><td>Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944&#8211;9.</td><td><a href=http://dx.doi.org/10.1038/nm0995-944>10.1038/nm0995-944</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_25</td><td>BibArticle</td><td>Nelson JB, Opgenorth TJ, Fleisher LA, Frank SM. Perioperative plasma endothelin-1 and big endothelin-1 concentrations in elderly patients undergoing major surgical procedures. Anesth Analg 1999;88:898&#8211;903.</td><td><a href=http://dx.doi.org/10.1213/00000539-199904000-00039>10.1213/00000539-199904000-00039</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, Year, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR11_25</td><td>BibArticle</td><td>Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/nm0198-050>10.1038/nm0198-050</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_25</td><td>BibArticle</td><td>Granchi S, Brocchi S, Bonaccorsi L, et al. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001;49:267&#8211;77.</td><td><a href=http://dx.doi.org/10.1002/pros.10022>10.1002/pros.10022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_25</td><td>BibArticle</td><td>Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_25</td><td>BibArticle</td><td>Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1a, TNF-a, and TGF-B in the PC3 human prostate cancer cell line. Cytokine 1999;11:157&#8211;62.</td><td><a href=http://dx.doi.org/10.1006/cyto.1998.0407>10.1006/cyto.1998.0407</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_25</td><td>BibArticle</td><td>Kobayashi S, Tang R, Wand B, et al. Localization of endothelin receptors in the human prostate. J Urol 1994;151:763&#8211;6.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16_25</td><td>BibArticle</td><td>Nelson JB, Lee W-H, Nguyen SH, et al. Methylation of the 5&#8242; CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997;57:35&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_25</td><td>BibArticle</td><td>Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975&#8211;86.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-03-3972>10.1158/0008-5472.CAN-03-3972</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18_25</td><td>BibArticle</td><td>Jeronimo C, Henrique R, Campos PF, et al. Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003;56:52&#8211;5.</td><td><a href=http://dx.doi.org/10.1136/jcp.56.1.52>10.1136/jcp.56.1.52</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_25</td><td>BibArticle</td><td>Pao MM, Tsutsumi M, Liang G, Uzvolgy E, Gonzales FA, Jones PA. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Genet 2001;10:903&#8211;10.</td><td><a href=http://dx.doi.org/10.1093/hmg/10.9.903>10.1093/hmg/10.9.903</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_25</td><td>BibArticle</td><td>Lo K-W, Tsang Y-S, Kwong J, To K-F, Teo PML, Huang DP. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 2002;95:651&#8211;5.</td><td><a href=http://dx.doi.org/10.1002/ijc.10271>10.1002/ijc.10271</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_25</td><td>BibArticle</td><td>Cohen AJ, Belinsky S, Franklin W, Beard S. Molecular and physiologic evidence for 5&#8242; CpG island methylation of the endothelin B receptor gene in lung cancer. Chest 2002;121:27S&#8211;8.</td><td><a href=http://dx.doi.org/10.1378/chest.121.3_suppl.27S>10.1378/chest.121.3_suppl.27S</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_25</td><td>BibArticle</td><td>Godara G, Cannon GW, Cannon GM, Bies RR, Nelson JB, Pflug B. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma. Prostate 2005;65:27&#8211;34.</td><td><a href=http://dx.doi.org/10.1002/pros.20252>10.1002/pros.20252</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_25</td><td>BibArticle</td><td>Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001;165:1033&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)66597-4>10.1016/S0022-5347(05)66597-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_25</td><td>BibArticle</td><td>Godara G, Pecher S, Jukic DM, et al. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology 2007;70:209&#8211;15.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2007.03.017>10.1016/j.urology.2007.03.017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_25</td><td>BibArticle</td><td>Kusuhara M, Yamaguchi K, Nagasaki K, et al. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257&#8211;61.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_25</td><td>BibArticle</td><td>Schichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 1991;87:1867&#8211;71.</td><td><a href=http://dx.doi.org/10.1172/JCI115210>10.1172/JCI115210</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_25</td><td>BibArticle</td><td>Nelson JB, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110&#8211;6.</td><td><a href=http://dx.doi.org/10.1038/nrc990>10.1038/nrc990</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_25</td><td>BibArticle</td><td>Brown KD, Littlewood CJ. Endothelin stimulates DNA synthesis in Swiss 3T3 cells. Synergy with polypeptide growth factors. Biochem J 1989;263:977&#8211;80.</td><td><a href=http://dx.doi.org/10.1042/bj2630977>10.1042/bj2630977</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, Year, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR29_25</td><td>BibArticle</td><td>Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996;379:557&#8211;60.</td><td><a href=http://dx.doi.org/10.1038/379557a0>10.1038/379557a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_25</td><td>BibArticle</td><td>Akhavan A, McHugh KH, Guruli G, et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006;8:725&#8211;32.</td><td><a href=http://dx.doi.org/10.1593/neo.06388>10.1593/neo.06388</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_25</td><td>BibArticle</td><td>Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67:3818&#8211;26.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-3879>10.1158/0008-5472.CAN-06-3879</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_25</td><td>BibArticle</td><td>Mabjeesh NJ, Shefler A, Amir S, Matzkin H. Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. Prostate 2008;68:679&#8211;89.</td><td><a href=http://dx.doi.org/10.1002/pros.20734>10.1002/pros.20734</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_25</td><td>BibArticle</td><td>Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005;7:631&#8211;7.</td><td><a href=http://dx.doi.org/10.1593/neo.04787>10.1593/neo.04787</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_25</td><td>BibArticle</td><td>Takuwa Y, Ohue Y, Takuwa N, Yamashita K. Endothelin-1 activiates phospholipase C and mobilizes Ca<Superscript>++</Superscript>from extra- and intracellular pools in osteoblastic cells. Am J Physiol 1989;257:E797&#8211;803.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR35_25</td><td>BibArticle</td><td>Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53:1063&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(98)00658-X>10.1016/S0090-4295(98)00658-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_25</td><td>BibArticle</td><td>Yin JJ, Mohammad KS, KaKonen SM, et al. A causal role of endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954&#8211;9.</td><td><a href=http://dx.doi.org/10.1073/pnas.1830978100>10.1073/pnas.1830978100</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_25</td><td>BibArticle</td><td>Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens 1990;8:811&#8211;7.</td><td><a href=http://dx.doi.org/10.1097/00004872-199009000-00004>10.1097/00004872-199009000-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_25</td><td>BibArticle</td><td>Raffa RB, Schupsky JJ, Lee DK, Jacoby HI. Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. J Pharmacol Exp Ther 1996;278:1&#8211;7.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR39_25</td><td>BibArticle</td><td>Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 1998;9:2279&#8211;83.</td><td><a href=http://dx.doi.org/10.1097/00001756-199807130-00025>10.1097/00001756-199807130-00025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51_25</td><td>BibArticle</td><td>Peters CM, Lindsay TH, Pomonis JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004;126:1043&#8211;52.</td><td><a href=http://dx.doi.org/10.1016/j.neuroscience.2004.04.027>10.1016/j.neuroscience.2004.04.027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_25</td><td>BibArticle</td><td>Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276:473&#8211;81.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR42_25</td><td>BibArticle</td><td>Verhaar MC, Grahn AY, van Weerdt AWM, et al. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol 2000;49:562&#8211;73.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2000.00171.x>10.1046/j.1365-2125.2000.00171.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_25</td><td>BibArticle</td><td>Samara E, Dutta S, Cao G, Granneman GR, Dordal MS, Padley RJ. Single-dose pharmacokinetics of atrasentan, and endothelin-A receptor antagonist. J Clin Pharmacol 2001;41:397&#8211;403.</td><td><a href=http://dx.doi.org/10.1177/00912700122010258>10.1177/00912700122010258</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_25</td><td>BibArticle</td><td>Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171&#8211;80.</td><td><a href=http://dx.doi.org/10.1200/JCO.2002.08.028>10.1200/JCO.2002.08.028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_25</td><td>BibArticle</td><td>Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9:2965&#8211;72.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR45_25</td><td>BibArticle</td><td>Carducci MA, Padley RJ, Breul J, et al. The effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, placebo controlled trial. J Clin Oncol 2003;21:679&#8211;89.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.04.176>10.1200/JCO.2003.04.176</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_25</td><td>BibArticle</td><td>Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003;169:1143&#8211;9.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000042162.08938.27>10.1097/01.ju.0000042162.08938.27</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_25</td><td>BibArticle</td><td>Carducci MA, Saad F, Abrahamsson P-A, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959&#8211;66.</td><td><a href=http://dx.doi.org/10.1002/cncr.22996>10.1002/cncr.22996</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_25</td><td>BibArticle</td><td>Nelson JB, Love W, Chin JL, et al. Phase 3, randomized controlled trial of atrasentan in patients with nonmetastatic hormone refractory prostate cancer. Cancer 2008;113(9):2478&#8211;87.</td><td><a href=http://dx.doi.org/10.1002/cncr.23864>10.1002/cncr.23864</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_25</td><td>BibArticle</td><td>James ND, Borre M, Zonnenberg B, et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases. Eur J Cancer Suppl 2007;5:3. Abstract 3LB.</td><td><a href=http://dx.doi.org/10.1016/S1359-6349(07)70096-4>10.1016/S1359-6349(07)70096-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_25</td><td>BibArticle</td><td>Nelson JB. Endothelin receptors as therapeutic targets in castration-resistant prostate cancer. Eur Urol Suppl 2009;8:20&#8211;8.</td><td><a href=http://dx.doi.org/10.1016/j.eursup.2008.10.004>10.1016/j.eursup.2008.10.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>